Compare BIO-TECHNE Corp (TECH) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Global X Uranium ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Global X Uranium ETF trades at $40.25. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Global X Uranium ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| TECH | URA | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $72.12 | $61.81 |
52-Week Low | $43.31 | $36.45 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend but oversold oscillators suggesting potential for a rebound. The fund's positioning in uranium and nuclear energy is buoyed by long-term demand drivers including AI power needs and government support, though key financial ratios are currently unavailable. Recent news highlights strong institutional interest in nuclear ETFs amid rising energy demands.
Outlook is cautiously optimistic given structural tailwinds for nuclear energy, but risks include regulatory shifts and uranium price volatility. The current bearish technical setup may present a buying opportunity if support levels hold, though investors should monitor earnings and expense ratios closely for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
